Nadeem Q. Mirza - 01 May 2024 Form 3 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: Chief Medical Officer
Signature: /s/ John P. Hamill, Attorney-in-Fact
Issuer symbol: APRE
Transactions as of: 01 May 2024
Transactions value $: $0
Form type: 3
Filing time: 02 May 2024, 16:15:12 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	APRE	Stock Option (Right to Buy)							01 May 2024	Common Stock	2.25K	$7.80	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent of the options vested on February 15, 2024, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued engagement with the Issuer through and including the applicable vesting dates and subject to acceleration under certain conditions. This option was granted to the Reporting Person while the Reporting Person was providing consulting services to the Issuer prior to his employment with the Issuer.

Content

Twenty-five percent of the options vested on February 15, 2024, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued engagement with the Issuer through and including the applicable vesting dates and subject to acceleration under certain conditions. This option was granted to the Reporting Person while the Reporting Person was providing consulting services to the Issuer prior to his employment with the Issuer.

Remarks:

Exhibit 24 - Power of Attorney